RARE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RARE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2025-03-16), Ultragenyx Pharmaceutical's share price is $39.34. Ultragenyx Pharmaceutical's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $-6.33. Therefore, Ultragenyx Pharmaceutical's PE Ratio without NRI for today is At Loss.
Ultragenyx Pharmaceutical's EPS without NRI for the three months ended in Dec. 2024 was $-1.37. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $-6.33.
As of today (2025-03-16), Ultragenyx Pharmaceutical's share price is $39.34. Ultragenyx Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-6.34. Therefore, Ultragenyx Pharmaceutical's PE Ratio (TTM) for today is At Loss.
Ultragenyx Pharmaceutical's EPS (Diluted) for the three months ended in Dec. 2024 was $-1.39. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-6.34.
Ultragenyx Pharmaceutical's EPS (Basic) for the three months ended in Dec. 2024 was $-1.39. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $-6.34.
The historical data trend for Ultragenyx Pharmaceutical's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
PE Ratio without NRI | Get a 7-Day Free Trial |
![]() |
![]() |
At Loss | At Loss | At Loss | At Loss | At Loss |
Ultragenyx Pharmaceutical Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
PE Ratio without NRI | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
At Loss | At Loss | At Loss | At Loss | At Loss |
For the Biotechnology subindustry, Ultragenyx Pharmaceutical's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Ultragenyx Pharmaceutical's PE Ratio without NRI falls into.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Ultragenyx Pharmaceutical's PE Ratio without NRI for today is calculated as
PE Ratio without NRI | = | Share Price | / | EPS without NRI |
= | 39.34 | / | -6.329 | |
= | -6.22(At Loss) |
Ultragenyx Pharmaceutical's Share Price of today is $39.34.
Ultragenyx Pharmaceutical's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.33.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Ultragenyx Pharmaceutical (NAS:RARE) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
Be Aware
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
Emil D Kakkis | director, 10 percent owner, officer: President & CEO | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Howard Horn | officer: Chief Financial Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Theodore Alan Huizenga | officer: Controller and PAO | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Sanders Corazon (corsee) D. | director | C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729 |
Karah Herdman Parschauer | officer: EVP and General Counsel | 60 LEVERONI COURT, NOVATO CA 94949 |
Eric Crombez | officer: EVP and Chief Medical Officer | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Thomas Richard Kassberg | officer: CBO & Senior Vice President | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Matthew K Fust | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Erik Harris | officer: EVP & Chief Commercial Officer | 60 LEVERONI COURT, NOVATO CA 94949 |
John Richard Pinion | officer: See Remarks | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Dennis Karl Huang | officer: SVP and Chief Tech Ops Officer | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Camille L Bedrosian | officer: EVP and Chief Medical Officer | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Mardi Dier | officer: CFO & Executive Vice President | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Amrit Ray | director | 60 LEVERONI COURT, NOVATO CA 94949 |
William Aliski | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
From GuruFocus
By Marketwired • 02-06-2025
By GuruFocus News • 12-19-2024
By GuruFocus News • 01-12-2025
By GuruFocus News • 12-19-2024
By Marketwired • 12-20-2024
By GuruFocus News • 01-17-2025
By GuruFocus News • 01-12-2025
By GuruFocus News • 12-20-2024
By GuruFocus News • 02-06-2025
By GuruFocus News • 02-10-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.